Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB’s rheumatoid arthritis drug Cimzia shows efficacy in new study

UCB’s rheumatoid arthritis drug Cimzia shows efficacy in new study

28th April 2011

UCB has published new data which showcases the quality of life benefits its drug Cimzia can deliver for rheumatoid arthritis patients.

A report in the Rheumatology medical journal, drawing on data from two phase III trials, has showed that Cimzia plus methotrexate can deliver improvements in terms of physical function, fatigue and pain among patients.

According to the new study, this has been associated with clear improvements in productivity within and outside the home, helping sufferers to work more effectively and also participate in family, social and leisure activities.

Dr Johanna Hazes, the paper's lead author, said: "The pain, fatigue and functional impairment caused by rheumatoid arthritis significantly impact patients' lives."

Cimzia is the only PEGylated anti-TNF therapy approved for the treatment of moderate-to-severe rheumatoid arthritis.

UCB states that high demand for the product was one of its key drivers of business growth during 2010.ADNFCR-8000103-ID-800514548-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.